Compounding Guide
Compounded Tirzepatide: What It Is, What It Costs, and What to Verify
Compounded tirzepatide is the lower-cost route to the active ingredient behind Zepbound and Mounjaro. Branded Zepbound costs about $1,060/month without insurance. Compounded versions run $200-600/month depending on dose and provider.
The catch: whether compounded tirzepatide is legal to dispense depends on whether tirzepatide is currently on the FDA drug shortage list. That status changed in late 2024 to early 2025. This page explains what that means and what to verify before ordering.
What is compounded tirzepatide?
Compounded tirzepatide is tirzepatide made by a compounding pharmacy from a raw active pharmaceutical ingredient (API). It is not manufactured by Eli Lilly. It is not FDA-approved.
The active ingredient is tirzepatide, the same peptide in Zepbound and Mounjaro. Compounding pharmacies typically use a salt form: tirzepatide diacetate or another form. The FDA considers these different from the base tirzepatide used in Lilly's branded products.
In practice, most patients and providers report comparable efficacy at equivalent doses. No FDA-validated head-to-head comparison has been published.
Legal status: the shortage rule
Federal law allows compounding pharmacies to make copies of FDA-approved drugs only under specific conditions. For 503A pharmacies (traditional compounders), one key condition is that the branded drug is on the FDA drug shortage list.
Tirzepatide (Mounjaro/Zepbound) was on the shortage list from 2023 through most of 2024. During that period, 503A compounding was widely available.
The FDA declared the shortage resolved in late 2024 to early 2025. After that point, 503A pharmacies face restrictions. 503B outsourcing facilities operate under different rules and may have more flexibility.
Cost comparison
| Option | Monthly cost | Availability |
|---|---|---|
| Branded Zepbound (no insurance) | ~$1,060/mo | Always available with Rx |
| Branded Zepbound (with savings card) | $550/mo cap | Commercial insurance only |
| Compounded tirzepatide (starting dose) | $199-299/mo | Subject to FDA shortage status |
| Compounded tirzepatide (therapeutic dose) | $350-600/mo | Subject to FDA shortage status |
Which providers offer compounded tirzepatide
Availability changes with FDA shortage status. Here are providers that have offered compounded tirzepatide:
| Provider | Compounded options | Starting price |
|---|---|---|
| Henry Meds | Tirzepatide (when available) | from $249/mo |
| Hims & Hers | Semaglutide primary; tirzepatide when available | from $149/mo |
| Mochi Health | Both, physician decision | from $99/mo + medication |
| Form Health | Both, insurance navigation first | from $149/mo + medication |
Check directly with each provider for current tirzepatide availability. Offerings change based on FDA shortage status.
What to verify before ordering
- Confirm current legal status. Ask your provider whether compounded tirzepatide is currently legal for their pharmacy to dispense. Get a clear yes with explanation.
- Know the pharmacy type. Is it a 503A traditional compounding pharmacy or a 503B FDA-registered outsourcing facility? The rules differ.
- Ask about the tirzepatide form. Is it tirzepatide diacetate or another salt form? This is different from the base form in Zepbound.
- Request quality documentation. Ask for a certificate of analysis (COA) showing third-party potency testing. A good pharmacy provides this.
- Confirm what happens if the shortage ends. Ask what your provider will do if the FDA removes tirzepatide from the shortage list mid-program.
Common questions
Is compounded tirzepatide legal in 2025?
It depends on the pharmacy type and current FDA shortage status. The FDA declared the tirzepatide shortage resolved in late 2024 to early 2025. After that, 503A compounding pharmacies face restrictions on compounding tirzepatide. 503B outsourcing facilities operate under different rules. Always verify current legal status with your telehealth provider before ordering.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
Not identical. Compounding pharmacies use tirzepatide salt forms (such as diacetate) as the active ingredient. The FDA considers these different from the base tirzepatide in Zepbound and Mounjaro. Most providers and patients report comparable appetite suppression and weight loss at equivalent doses, but no FDA-validated head-to-head comparison exists.
How much does compounded tirzepatide cost?
Prices range from $199 to $600/month depending on provider, dose, and whether you are on a starting or therapeutic dose. Starting doses (2.5mg) typically run $199-299/month. Therapeutic doses (7.5mg-15mg) can reach $400-600/month. This compares to branded Zepbound at approximately $1,060/month without insurance.
What should I ask before ordering compounded tirzepatide?
Ask your provider: Is compounded tirzepatide currently legal for your pharmacy to dispense? What pharmacy type are they using (503A or 503B)? What tirzepatide salt form is used? What third-party testing is done on each batch? Can you see a certificate of analysis?
What happens if I am on compounded tirzepatide and the shortage ends?
Your provider should notify you. If the FDA declares the shortage resolved for 503A purposes, your pharmacy may need to stop compounding. Your provider will typically offer to transition you to branded Zepbound through insurance navigation, or to compounded semaglutide as an alternative.